Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hearing Loss
- Sponsor
- Advanced Bionics
- Enrollment
- 67
- Locations
- 11
- Primary Endpoint
- Unaided Pure-tone Average (PTA) Hearing Threshold Measurements
- Status
- Terminated
- Last Updated
- 11 months ago
Overview
Brief Summary
The purpose of this feasibility study is to evaluate whether low-frequency acoustic hearing sensitivity can be preserved in newly implanted adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) using the HiResolution™ 90K™ Advantage cochlear implant with the HiFocus™ Mid-Scala electrode to support the development of electro-acoustic stimulation technology (EAS).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Newly Implanted and Existing Implanted Groups
- •Ability to provide informed consent
- •18 years of age or older, unilaterally implanted with HiRes90K™ Advantage cochlear implant with HiFocus™ Mid-Scala electrode and fit with an ear-level sound processor (i.e. Naída family device)
- •Postoperative unaided low frequency audiometric hearing thresholds in the treated ear up to 80 dB HL for at least one frequency from 125 - 1000 Hz
- •English Language Proficiency
- •Willingness to participate in all scheduled procedures outlined in the study protocol
- •EAS Fitting
Exclusion Criteria
- •Newly Implanted and Existing Implanted Groups
- •Unilaterally implanted with HiRes 90K™ Advantage cochlear implant with HiFocus™ Helix® and HiFocus™ 1j electrode
- •Exclusive use of a body worn external sound processor
- •Deafness due to central auditory lesion or cochlear nerve deficiency, diagnosis of auditory neuropathy/dys-synchrony in either the implanted or the contralateral ear
- •Postoperative unaided low frequency audiometric hearing thresholds in the treated ear exceeding 80 dB HL at each frequency from 125 - 1000 Hz Unwillingness or inability of subject to comply with all investigational requirements as determined by the investigator
Outcomes
Primary Outcomes
Unaided Pure-tone Average (PTA) Hearing Threshold Measurements
Time Frame: Twelve months post device activation
Unaided pure tone hearing threshold measurement in the implanted ear at months 3, 6 and 12 months after surgery compared to pre-implant audiometric thresholds (using pure-tone average of 125 - 1000 Hz for comparison)
Consonant-Nucleus-Consonant (CNC) Word Recognition Test in Quiet
Time Frame: Up to 12 months post device activation
Consonant-Nucleus-Consonant (CNC) Word Recognition Test in quiet in the treated ear measured at Month 1, 3, 6 and 12 post device activation compared to pre-implant speech perception testing in quiet. Scores are determined on scale of 0% to 100% words correct with higher scores indicating a better outcome.
Speech Perception Testing (AzBio) in Noise.
Time Frame: up to 12 months post device activation
Speech perception testing (AzBio) in noise in the treated ear measured at Month 1, 3, 6 and 12 post device activation compared to pre-implant speech perception testing in quiet. Scores are determined on scale of 0% to 100% words correct with higher scores indicating a better outcome.